Core Insights - Philips has demonstrated strong order growth and sales in 2025, with a robust balance sheet and margin expansion despite external challenges [2][6][7] Financial Performance - For the full year 2025, comparable order intake increased by 6%, while comparable sales growth was 2%. In Q4, comparable order intake rose by 7%, and group sales reached EUR 5.1 billion, reflecting a 7% increase [6][7] - Adjusted EBITA margin improved by 80 basis points to 12.3% for the full year and by 160 basis points to 15.1% in Q4, driven by higher sales and productivity [6][7] - Free cash flow for 2025 was EUR 512 million, with Q4 free cash flow at EUR 1,200 million [6][8] Segment Performance - Diagnosis & Treatment segment saw a 4% increase in comparable sales in Q4, with an adjusted EBITA margin of 11.8% [9] - Connected Care segment experienced a 7% increase in comparable sales in Q4, with an adjusted EBITA margin of 16.5% [10] - Personal Health segment reported a 14% increase in comparable sales in Q4, with an adjusted EBITA margin of 23.0% [11] Innovation and Strategic Initiatives - Philips launched several innovations, including the Azurion neuro biplane platform and a helium-free 3.0T MR system, enhancing its product offerings in healthcare [3][15] - The company has entered a five-year strategic partnership with AdventHealth to upgrade patient monitoring systems across its network [15] - Philips aims to drive profitable growth through segment-specific strategies, innovation, and disciplined execution, with a focus on integrating AI and data into healthcare solutions [19][20][21] Future Outlook - For 2026, Philips anticipates mid-single-digit comparable sales growth CAGR and a mid-teens adjusted EBITA margin by 2028 [24][23] - The company plans to achieve cumulative free cash flow of EUR 4.5-5.0 billion over the 2026-2028 period and EUR 1.5 billion in productivity savings [24]

Core Viewpoint - Royal Philips has been recognized as a Clarivate Top 100 Global Innovator for 2026, marking the 13th consecutive year of this achievement, highlighting its leadership in healthcare innovation [2][6]. Group 1: Innovation and R&D Commitment - Philips invests over EUR 1.7 billion annually in R&D, which is approximately 9% of its sales, positioning it among the highest in the industry [3][6]. - The company focuses on AI-enabled technologies, advanced imaging, and connected platforms to enhance diagnosis precision and streamline workflows [3][6]. Group 2: Notable Innovations - Philips Verida is introduced as the world's first detector-based spectral CT, integrating AI throughout the imaging process [7]. - The company has developed helium-free MRI magnet technology, saving over six million liters of liquid helium and eliminating the need for refills in hospitals [7]. - The Philips Flash 5100 Point-of-Care Ultrasound offers advanced imaging clarity and an intuitive workflow for frontline clinical decision-making [7]. - A next-generation web-based diagnostic viewer has been created to improve how radiologists access and interpret medical images [7]. - AI-enabled personal care innovations, such as the Philips i9000 Shaver Series, provide personalized self-care experiences for consumers [7]. Group 3: Company Overview - Philips generated sales of EUR 18 billion in 2024 and employs approximately 67,000 people, with operations in over 100 countries [8].

Core Insights - Royal Philips has launched Verida, the world's first detector-based spectral CT fully powered by AI, marking a significant advancement in CT technology [1][6] - The integration of AI optimizes the imaging chain, resulting in lower system noise, improved image quality, and faster clinical workflows [1][3] Company Overview - Royal Philips is a global leader in health technology, focusing on improving health and well-being through innovation [13][14] - The company generated sales of EUR 18 billion in 2024 and employs approximately 67,000 people across more than 100 countries [14] Product Features - Verida features AI-driven spectral precision, enabling superior image quality and accelerated scans, fully integrated into radiology workflows [5][6] - The system can reconstruct 145 images per second, allowing for exams to be completed in less than 30 seconds, effectively doubling the speed of previous systems [4][6] - Verida can achieve a dose reduction of up to 80% and reduce energy consumption by up to 45% [3][11] Clinical Impact - The introduction of Verida is expected to enhance diagnostic confidence and reduce the need for invasive procedures, particularly in cardiac imaging [4][5] - The system has been designed to meet the demands of high-throughput environments, allowing up to 270 exams per day [11] Market Position - Philips has pioneered detector-based spectral CT technology, which has been widely adopted in clinical settings, supported by over 800 peer-reviewed publications [2][8] - The company emphasizes that its spectral CT technology has been a reliable clinical tool for over a decade, providing comparable or superior clinical outcomes at a lower total cost of ownership [5][6]